Leukoencephalopathies are disorders that selectively involve the white matter of the brain. Acquired causes of leukoencephalopathy include inflammatory conditions, infections, vascular disorders, neoplasia, and toxic causes. Hereditary leukoencephalopathies encompass those conditions that demonstrate progressive destruction or loss of previously acquired myelin (leukodystrophies) as well as those conditions associated with impaired formation of myelin (dysmyelination or hypomyelination). The study of clinical features, neuroimaging patterns, and biochemical and neuropathologic features of leukoencephalopathies has led to the discovery of the genetic defects responsible for many of these conditions. Variations in phenotype-genotype correlation can make the prediction of the underlying condition challenging. Despite recent advances in molecular studies, 50% of patients with hereditary leukoencephalopathies remain undiagnosed. A systematic approach to guide investigations is important to lead to a diagnosis.
Clinical History
The temporal evolution of neurologic and nonneurologic symptoms can be helpful when attempting to categorize leukoencephalopathies. The age of onset may be neonatal (or prenatal), infantile, late-infantile, childhood, or it may occur in adulthood after a long period of normalcy. Neurologic symptoms may be static, gradually improving over time or progressively declining. The pattern of skill acquisition in children is particularly important because some conditions present with development that is delayed but where children continue to steadily gain skills at their own pace. Other conditions, particularly those associated with progressive destruction of myelin, frequently present with a period of normal development followed by a plateau in skill acquisition then a decline. It is important to note whether there is a regression of skills associated with fever, infections, or head injuries. A careful review of systems aimed at detecting neurologic and nonneurologic symptoms helps generate possible clues for pattern recognition.
A family history of a similarly affected sibling, parent, or family member increases the likelihood of an inherited form of leukoencephalopathy and may suggest the inheritance pattern (autosomal dominant, autosomal recessive, X-linked, or mitochondrial). Some hereditary leukoencephalopathies have primarily been described in specific ethic groups. It is therefore important to enquire about ethnicity and consanguinity.
Physical Examination
A careful physical examination including general, neurologic, and ophthalmologic examinations can yield important clues to the underlying diagnosis. . These may be difficult to treat with standard dermatologic approaches suggesting the possibility of an underlying condition. Bronzing of the skin may be a clue to adrenal insufficiency in patients with peroxisomal disorders, including X-linked adrenoleukodystrophy and peroxisomal biogenesis defects. 4. Assessment of other organ systems: Hepatomegaly or hepatosplenomegaly may be an indication of a lysosomal storage disorder or peroxisomal disorder. Mitochondrial disorders can involve multiple organs including the liver, kidneys, or heart. 5. Ophthalmology examination: The eye has been described as the window to the brain. Ophthalmologic manifestations involving the cornea, lens, retina, and optic nerve are present in several inborn errors of metabolism associated with leukoencephalopathy. 1 Retinal vascular changes have been described in leukoencephalopathies associated with hereditary small vessel diseases.
2 Ophthalmologic manifestations associated with leukoencephalopathies are listed in ►Table 3. 6. Neurologic features: Although progressive spasticity is one of the hallmark signs of leukodystrophy, patients may present with hypotonia or a mixed tone disorder (central hypotonia with increased tone in the extremities). Dystonia or rigidity may also be present depending on the underlying cause of the leukoencephalopathy. Peripheral neuropathy coexists in several leukoencephalopathies, which may result in decreased deep tendon reflexes despite the presence of spasticity (►Table 4). Myopathy may also be present and may be detected on electromyography (EMG) or by an elevated creatine kinase. Focal 
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The term demyelination refers to the loss or damage of previously formed myelin. Acute demyelination secondary to acquired causes, such as infections or inflammatory conditions, including multiple sclerosis and acute disseminated encephalomyelitis (ADEM), is generally asymmetric and nonconfluent (►Fig. 1). Chronic demyelination associated with inherited leukoencephalopathies is more commonly bilateral, symmetric, and confluent in distribution (►Fig. 2). Regions of demyelination have increased signal intensity on magnetic resonance imaging (MRI) fluid-attenuated inversion recovery (FLAIR) imaging and may be accompanied by contrast enhancement or restricted diffusion. Defects of myelin biosynthesis and metabolism result in dysmyelination, which may coexist with demyelination or hypomyelination. Hypomyelination refers to a lack of myelin formation. Patients with delayed myelination demonstrate a gradual increase in myelin over time, which is delayed in maturity for age. Serial MRI scans at least 6 months apart are required to distinguish between hypomyelination and delayed myelination. On MRI scan, hypomyelination has the signal intensity of immature white matter and is inconspicuous on FLAIR. Conditions associated with hypomyelination are listed in ►Table 5.
Calcifications are more clearly ascertained using computed tomography (CT) scan imaging than MRI. The differential diagnosis of central nervous system calcifications includes congenital disorders such as Sturge-Weber syndrome and tuberous sclerosis; infectious causes including TORCH infections, disorders of parathyroid metabolism, and calcifications associated with neoplasms and vascular disorders. 7 AicaridiGoutieres syndrome is an autosomal recessive condition, associated with at least four different genes, presenting with an early encephalopathy followed by stabilization of neurologic symptoms. Neuroimaging reveals leukoencephalopathy with calcifications and cerebral atrophy. Cerebrospinal fluid analysis reveals chronic lymphocytosis, elevated INF-α, and neopterin. [8] [9] [10] [11] Other leukoencephalopathies associated with calcifications are listed in ►Table 6. Cystic changes may be characteristic of the underlying condition or may represent progressive cystic degeneration of the white matter (►Table 7). Investigations 1. First tier a. Test creatine kinase if symptoms of myopathy/muscular dystrophy are present. b. Lactate and pyruvate may be abnormal in mitochondrial and related disorders. c. Quantitative amino acids, total plasma homocysteine, folate, and vitamin B12 levels detect disorders of amino acid metabolism and homocystinuria associated with disorders of vitamin B12 and folate metabolism. d. Urine organic acids may detect elevated NAA levels characteristic of Canavan's disease in addition to organic acid disorders associated with leukoencephalopathy, including glutaric aciduria type 1, L-2-hydroxyglutaric aciduria, 3-methylglutaconic aciduria type 1, and biotinidase deficiency. e. Very long chain fatty acids, pipecolic acid, phytanic acid, and other peroxisomal studies detect X-linked adrenoleukodystrophy, peroxisomal biogenesis defects, and single peroxisomal enzyme defects. f. Urine may be tested for mucopolysaccharides, oligosaccharides, sulfatides (for metachromatic leukodystrophy), and ceramides (for Fabry's disease). 
Conclusion
A systematic approach to the clinical and neuroimaging findings in patients with leukoencepholopathy helps guide investigations leading to a specific diagnosis.
